CyFlow™ CD21 FITC

CyFlow™ CD21 FITC
Laser: Blue
Target Species: Cow, Dog, Human, Pig
Antigen: CD21
Field of Interest: Immunophenotyping
Clone: LT21
Regulatory Status: RUO
Alternative Name: C3dR, CR2, EBV-R
Application: Flow cytometry
Format/Fluorochrome: FITC
Species of Origin: Mouse
Clonality: monoclonal
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Isotype: IgG1
Product number: AD176164

For Research Use Only

$235.00 USD*

Price excludes any applicable taxes plus shipping costs

HLDA Workshop HLDA VI—WS Code B CD21.1 Quantity 100 tests Immunogen IM9 human... more
CyFlow™ CD21 FITC
HLDA WorkshopHLDA VI—WS Code B CD21.1
Quantity100 tests
ImmunogenIM9 human B-lymphoblastoid cell line
SpecifityThe mouse monoclonal antibody LT21 recognizes CD21 antigen, a 145 kDa transmembrane glycoprotein (complement C3d receptor - C3dR) expressed on B lymphocytes, follicular dendritic cells, some epithelial cells and a subsets of T lymphocytes. It is not expressed on immature B cells.
Background InformationCD21 (CR2; complement receptor 2) binds C3 complement fragments, especially its breakdown fragments, which remain covalently attached to complement activating surfaces or antigen. CD21 has important roles in uptake and retention of immunocomplexes, survival of memory B cells and in development and maintenance of the humoral response to T-dependent antigens. CD21 also serves as a key receptor for Epstein-Barr virus binding and is involved in targeting prions to folicular dendritic cells and expediting neuroinvasion following peripheral exposure to prions. A soluble form of the CD21 (sCD21) is shed from the lymphocyte surface and retains its ability to bind respective ligands.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland·Publishing·Inc,·New·York. 1997; 1‑1342. <·NLM·ID:·9712219·> | Kasprzak A, Spachacz R, Wachowiak J, Stefanska K, Zabel M: Epstein‑Barr virus (EBV) infection in B‑cell non‑Hodgkin's lymphomas in children: virus latency and its correlation with CD21 and CD23 molecules. Folia·Histochem·Cytobiol. 2007; 45(3):169‑79. <·PMID:·17951165·> | Filatov AV, Krotov GI, Zgoda VG, Volkov Y: Fluorescent immunoprecipitation analysis of cell surface proteins: a methodology compatible with mass‑spectrometry. J·Immunol·Methods. 2007·Jan·30; 319(1‑2):21‑33. <·PMID:·17098248·> | Twohig J, Kulik L, Haluszczak C, Reuter J, Rossbach A, Bull M, Holers VM, Marchbank KJ: Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21 transgenic mice is partially recovered in the absence of C3. Mol·Immunol. 2007·Jul; 44(13):3434‑44. <·PMID:·17379312·> | Faldyna M, Samankova P, Leva L, Cerny J, Oujezdska J, Rehakova Z, Sinkora J: Cross‑reactive anti‑human monoclonal antibodies as a tool for B‑cell identification in dogs and pigs. Vet·Immunol·Immunopathol. 2007·Sep·15; 119(1‑2):56‑62. <·PMID:·17673300·> | Roozendaal R, Carroll MC: Complement receptors CD21 and CD35 in humoral immunity. Immunol·Rev. 2007·Oct; 219:157‑66. <·PMID:·17850488·> | Zabel MD, Heikenwalder M, Prinz M, Arrighi I, Schwarz P, Kranich J, von Teichman A, Haas KM, Zeller N, Tedder TF, Weis JH, Aguzzi A: Stromal complement receptor CD21/35 facilitates lymphoid prion colonization and pathogenesis. J·Immunol. 2007·Nov·1; 179(9):6144‑52. <·PMID:·17947689·> | Singh A, Blank M, Shoenfeld Y, Illges H: Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti‑beta2‑glycoprotein‑I autoantibodies. Rheumatol·Int. 2008·Jan·3; <·PMID:·23949624·>

Article successfully added.